MC# 22-36 - An Open-Label Phase Ib Study of E7386 in Combination With Other Anticancer Drug(s) in Subjects With Solid Tumors

  • Agent(s): E7386
  • Disease Type(s): Colorectal, Endometrial, Hepatocellular
  • Phase(s): I
  • Drug Classification(s): Small Molecule, Targeted Therapy
  • Molecular Target(s): β-catenin

Mechanism of Action

E7386 inhibits beta-catenin and prevents the interaction of beta-catenin with its transcriptional coactivator, CREB (cAMP response element-binding) binding protein (CBP). This prevents binding of beta-catenin/CBP to WRE (Wnt-responsive element), and inhibits the activation of transcription of a wide range of target genes of Wnt/beta-catenin signaling, thereby preventing gene expression of many Wnt-related, pro-survival proteins and suppressing tumor cell growth.

Lenvatinib (E7080) is an orally available potent inhibitor of the split-kinase family of transmembrane growth factor receptors including Flt-1/VEGFR-1 and KDR/VEGFR-2.


In this study, the sponsor and investigators want to learn:

  • How much of E7386 can be given with an acceptable level of side effects in combination with other anticancer drug(s)
  • The effects of E7386 (good and bad) in combination with other anticancer drug(s)
  • How much of E7386 is absorbed into the blood and how fast it is removed
Inclusion Criteria
  1. HCC part only: Participants with confirmed diagnosis of unresectable HCC with any of the following criteria:
    1. Histologically or cytologically confirmed diagnosis of HCC, excluding fibrolamellar, sarcomatoid or mixed cholangio-HCC tumors
    2. Clinically confirmed diagnosis of HCC according to American Association for the Study of Liver Diseases (AASLD) criteria, including cirrhosis of any etiology and/or chronic hepatitis B or C infection
  2. ST part only (except for HCC): Participants with histologically or cytologically confirmed diagnosis of solid tumor for which no alternative standard therapy or no effective therapy exists
  3. Life expectancy of ≥12 weeks
  4. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 1
  5. All AEs due to previous anti-cancer therapy have either returned to Grade 0 to 1 except for alopecia or up to Grade 2 peripheral neuropathy (renal/bone marrow/liver function should meet the inclusion criteria)
  6. Adequate washout period before study drug administration:
    1. Chemotherapy and radiotherapy: 3 weeks or 5 times the half-life, whichever is shorter
    2. Any antitumor therapy with antibody: 4 weeks or more
    3. Any investigational drug or device: 4 weeks or more
    4. Blood/platelet transfusion or granulocyte colony-stimulating factor (G-CSF): 2 weeks or more Note: Participants must have recovered from all radiation-related toxicities, not require corticosteroids, and not had radiation pneumonitis
  7. Adequate controlled blood pressure (BP), renal function, bone marrow function, liver function, and serum mineral level
  8. At least one measurable lesion based on RECIST 1.1 meeting following criteria
    1. At least 1 lesion of ≥1.0 centimeter (cm) in the longest diameter for a non-lymph node or ≥1.5 cm in the short-axis diameter for a lymph node that is serially measurable according to RECIST 1.1 using computerized tomography (CT)/magnetic resonance imaging (MRI)
    2. Lesions that have had external beam radiotherapy or loco-regional therapies such as radiofrequency ablation, or transarterial chemoembolisation (TACE)/ transarterial embolization (TAE) must show evidence of progressive disease based on RECIST 1.1 to be deemed a target lesion
  9. For HCC participants only: Child-Pugh score A
  10. For HCC participants only: Participants categorized to stage B (not applicable for trans arterial chemoembolization), or stage C based on Barcelona Clinic Liver Cancer (BCLC) staging system
  11. For HCC Subpart in Expansion Part only: prior systemic therapy for locally advanced or metastatic disease is as defined below
    1. Participants who have received only one prior line of immuno oncology (IO) based regimen and have progressed on or after prior treatment with IO based regimen, or IO ineligible participants who have received no prior systemic therapy. Participants who previously received lenvatinib treatment are ineligible.
  12. For CRC Subpart in Expansion Part only: participants must have received at least 2 prior regimens (not exceeding 4 prior regimens) or could not tolerate standard treatment and must have received the following prior therapies in the adjuvant and/or metastatic setting if approved and locally available (progressed on at least 1 prior regimen in the metastatic setting or could not tolerate standard treatment):
    1. Note: Adjuvant chemotherapy counts as prior systemic treatment if there is documented disease progression within 6 months of treatment completion Note: If a participant is determined to be intolerant to prior standard treatment, the participant must have received at least of 2 cycles of that therapy Note: Participants who have received oral tyrosine kinase inhibitor (example, regorafenib) are ineligible
      1. Fluoropyrimidine, irinotecan and oxaliplatin Note: Capecitabine is acceptable as equivalent to fluoropyrimidine in prior treatment Note: Participants who have previously received fluoropyrimidine, oxaliplatin, and irinotecan as part of the same and only chemotherapy regimen, example, FOLFOXIRI or FOLFIRINOX, may be eligible after discussion with the Sponsor
      2. Chemotherapy with or without an anti-vascular endothelial growth factor receptor (VEGF) monoclonal antibodies (mAb) (example, bevacizumab)
      3. Chemotherapy with anti- epidermal growth factor receptor (EGFR) mAb (cetuximab or panitumumab) for participants with rat sarcoma virus (RAS) (Kirsten rat sarcoma viral oncogene homolog [KRAS)/ NRAS]) wild type (WT) CRC Note: RAS (KRAS/NRAS) WT participants with right or left CRC lesions who may have not been treated with anti-EGFR mAb based on local guidelines are eligible
      4. BRAF inhibitor (in combination with cetuximab ± binimetinib) for BRAF V600E mutated tumors
      5. Immune checkpoint inhibitor for participants with microsatellite instability-high (MSI-H) CRC
  13. For EC Subpart in Expansion Part only: Participants who have radiographic evidence of disease progression after prior systemic therapies. Participants must have received platinum-based chemotherapy regimen and/or IO based regimen (example, lenvatinib + pembrolizumab or pembrolizumab monotherapy) for EC. Participants may have received up to 1 additional line of platinum-based chemotherapy if given in the neoadjuvant or adjuvant treatment setting, but not exceeding 3 lines of therapies. If participants are ineligible for IO therapy, participants who have received only 1 prior systemic therapy including platinum based chemotherapy regimen are eligible Note: There is no restriction regarding prior hormonal therapy
Exclusion Criteria
  1. Any of cardiac conditions as follows:
    1. Heart failure New York Heart Association (NYHA) Class II or above
    2. Unstable ischaemic heart disease (myocardial infarction within 6 months prior to starting study drug, or angina requiring use of nitrates more than once weekly)
    3. Prolongation of QT interval with Fridericias correction (QTcF) to greater than (>) 480 millisecond (msec)
    4. Left ventricular ejection fraction (LVEF) less than 50 percent (%)
  2. Major surgery within 21 days prior to starting study drug. Participant must have recovered from the surgery related toxicities to less than Grade 2.
    1. Note: Adequate wound healing after major surgery must be assessed clinically, independent of time elapsed for eligibility
  3. Known to be human immunodeficiency virus (HIV) positive Note: the sponsor has evaluated whether to include participant with HIV. Given that this is the first combination study of E7386 with lenvatinib and that the main mechanism of action of E7386 is immunomodulation of the tumor microenvironment along with the fact that several anti-retroviral therapies have drug-drug interaction with cytochrome P450 3A (CYP3A) substrates, the sponsor has decided not to include these participants at the current time. However, further considerations will be made moving forward based on new emerging data Note: HIV testing is required at screening only when mandated by local health authority
  4. Participants with proteinuria >1 positive on urine dipstick testing will undergo 24-hour urine collection for quantitative assessment of proteinuria. Participants with urine protein ≥1 gram per 24 hour will be ineligible
  5. Active infection requiring systemic treatment (Except for Hepatitis B and/or C [HBV/HCV] infection in HCC participants. In case of HBsAg (+) participants in HCC participants:
    1. Antiviral therapy for HBV is not ongoing
    2. HBV viral load is 2000 international unit per milliliter (IU/mL) or more at the Screening Period although antiviral therapy for HBV is ongoing
    3. Has dual active HBV infection (HBsAg (+) and/or detectable HBV deoxyribonucleic acid [DNA]) and HCV infection (anti-HCV Ab (+) and detectable HCV ribonucleic acid [RNA]) at study entry
  6. Diagnosed with meningeal carcinomatosis
  7. Participants with brain or subdural metastases are not eligible, unless they have completed local therapy and have discontinued the use of corticosteroids for this indication for at least 4 weeks before starting treatment in this study. Any signs (example, radiologic) or symptoms of brain metastases must be stable for at least 4 weeks before starting study treatment
  8. Pulmonary lymphangitic involvement that results in pulmonary dysfunction requiring active treatment, including the use of oxygen
  9. Any of bone disease/conditions as follows:
    1. Osteoporosis with T-score of < minus (-) 2.5 at the left or right total hip, left or right femoral neck or lumbar spine (L1-L4) as determined by dual energy x-ray absorptiometry (DXA) scan
    2. Fasting beta-CTX (serum) >1000 picogram per milliliter (pg/mL) (that is, 1000 nanogram per liter [ng/L])
    3. Metabolic bone disease, such as hyperparathyroidism, Paget's disease or osteomalacia
    4. Symptomatic hypercalcemia requiring bisphosphonate therapy
    5. History of any fracture within 6 months prior to starting study drug
    6. Bone metastasis requiring orthopedic intervention
    7. Bone metastasis not treated by bisphosphonate or denosumab (except for lesion treated by radiation)
    8. History of symptomatic vertebral fragility fracture or any fragility fracture of the hip, pelvis, wrist or other location (defined as any fracture without a history of trauma or because of a fall from standing height or less)
    9. Moderate (25% to 40% decrease in the height of any vertebrae) or severe (>40% decrease in the height of any vertebrae) morphometric vertebral fracture at baseline
  10. Bleeding or thrombotic disorders or use of anticoagulants requiring therapeutic International Normalized Ratio (INR) monitoring for HCC participants only (example, warfarin or similar agents). Treatment with low molecular weight heparin and factor X inhibitors is permitted. Treatment with antiplatelet agents is prohibited for HCC participants only.
  11. Gastrointestinal bleeding event or active hemoptysis (bright red blood of at least 0.5 teaspoon) within 3 weeks prior to the first dose of study drug
  12. For EC Subpart in Expansion Part only: carcinosarcoma (malignant mixed Mullerian tumor), endometrial leiomyosarcoma, and endometrial stromal sarcomas
  13. Has preexisting >=Grade 3 gastrointestinal or non-gastrointestinal fistula
  14. Evidence of current COVID-19 infection or ongoing unrecovered active sequelae of COVID-19 infection
  15. Males who have not had a successful vasectomy (confirmed azoospermia) if their female partners meet the exclusion criteria above (that is, the female partners are of childbearing potential and are not willing to use a highly effective contraceptive method throughout the study period and for 30 days after study drug discontinuation). No sperm donation is allowed during the study period and for 30 days after study drug discontinuation
  16. Has a known psychiatric or substance abuse disorder that would interfere with the participant ability to cooperate with the requirements of the study
  17. Evidence of clinically significant disease (example, cardiac, respiratory, gastrointestinal, renal disease) that in the opinion of the investigator could affect the participant safety or interfere with the study assessments
  18. Scheduled for major surgery during the study


  • Dallas, TX - Mary Crowley Cancer Research - Medical City
More Info:

Contact Us About This Trial

Reach out to us by sharing your info in the form below or give us a call at 972-566-3000.

Re: MC# 22-36